Refine by
Type I Diabetes Articles & Analysis
134 news found
Protheragen-ING, a distinguished name in the realm of pharmaceutical innovation, has proudly announced its most sought-after Active Pharmaceutical Ingredients (APIs). Known for offering tailored technical research and development services to researchers globally, Protheragen-ING emphasizes its commitment to pioneering advancement in pharmaceutical sciences. Among the top APIs highlighted are ...
We’re starting the week by welcoming Rebecca Warfvinge and João Vieira to the BPC team! Both join us as Technical Sales Scientists, bringing research expertise that will help our customers advance their work. Rebecca holds a master’s degree in biomedicine and has since conducted research for several years at Lund University in leukemia, where she used single-cell methods to ...
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. Diabetes mellitus, a chronic condition characterized by elevated blood ...
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options. ...
Creative Enzymes, a leading provider of high-quality enzymes and biochemicals, is proud to announce the addition of Semaglutide to its comprehensive product portfolio. This novel glucagon-like peptide-1 (GLP-1) receptor agonist has generated significant excitement within the pharmaceutical and life sciences industries due to its remarkable efficacy in managing type 2 diabetes. Semaglutide ...
Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain. This groundbreaking addition to Huateng Pharma's esteemed portfolio signifies a remarkable leap forward in pharmaceutical innovation, showcasing a diverse array of compounds including AEEA-AEEA (CAS NO.: 1143516-05-5), SNAC (CAS NO.: 203787-91-1), ...
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
ByBayer AG
Alertgy has nearly completed the process of miniaturizing its first generation NICGM® (Non-Invasive Continuous Glucose Monitor) into a smaller form factor that will be the size of modern smart watches. By replacing commercial off-the-shelf components with custom built parts, Alertgy has been able to greatly reduce the size of its NICGM. Throughout the design process, Alertgy has aimed to ...
ByAlertgy
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study FIGARO-DKD included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD ...
ByBayer AG
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma ...
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the ...
ByBayer AG
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a ...
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
A 1% percent mean reduction in A1c was observed in patients with Type 2 diabetes using the OneTouch Reveal mobile app and a Bluetooth® connected meter after 3 months in a clinical study (n=23)*. ...
ByLifeScan
“It is with great pleasure that I welcome both Ed and Nanna to our Board of Directors at this exciting time for the Company”, said François Ravenelle, PhD, Chief Executive Officer of Inversago Pharma. ...
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). As communicated on 23 September 2021, ...
Results of an analysis of a previous prevention trial with Diamyd® (GAD-alum) treatment, which indicate a positive and sustained immunomodulating effect after treatment with Diamyd® in healthy children at risk for type 1 diabetes, have been published in the scientific journal Journal of Immunology Research. The analysis was carried out by researchers at Lund University and provides ...
“On behalf of all of us at Inversago Pharma, I accept this prestigious award with honor and pride”, said François Ravenelle, PhD, Chief Executive Officer of Inversago Pharma. ...
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry the genetic HLA DR3-DQ2 haplotype. DIAGNODE-B (B for “booster”) assesses ...